Boston Medical Center / Boston University
Hematology and Oncology fellowship · Boston, MA · Program website
Roster not collected yet. There's no list of this program's own faculty, trainees, or papers yet. Below is Boston Medical Center's research in hematology and oncology, which the program shares with other departments and affiliated hospitals.
About Boston Medical Centerinstitution-wide hematology and oncology research
Hematology and Oncology publications from Boston Medical Center and affiliated institutions, since 2022. Updated 2026-11-07; refreshed daily.
66
works per year
49th of 74 hematology and oncology fellowship programs
-8.8%
2-year growth
68th of 74 hematology and oncology fellowship programs
17.4%
in top 10% of field (works before 2025)
51st of 72 hematology and oncology fellowship programs
43.5%
cited above world average
34th of 72 hematology and oncology fellowship programs
Works per year · * 2026 so far
Oncology · 265Hematology · 86
Hematology and Oncology research topics at Boston Medical Center
Papers in the window; each links to the list on OpenAlex.
- COVID-19 and healthcare impacts 32
- Multiple Myeloma Research and Treatments 28
- Colorectal Cancer Screening and Detection 27
- Neuroendocrine Tumor Research Advances 27
- Global Cancer Incidence and Screening 18
- Cancer Immunotherapy and Biomarkers 17
- Colorectal Cancer Surgical Treatments 17
- Cutaneous Melanoma Detection and Management 17
Most cited at Boston Medical Center since 2024
All hematology and oncology papers there on OpenAlex
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine TumorsJennifer Ai-wen Chan et al. · New England Journal of Medicine · 2024 · PubMed · cited 177
- PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast CancerErica L. Mayer et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 137
- Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R. Gandara et al. · Journal for ImmunoTherapy of Cancer · 2025 · PubMed · cited 61
- Role of minimal residual disease assessment in multiple myelomaRaphael Elie Szalat et al. · Haematologica · 2024 · PubMed · cited 45
- CT Colonography Reporting and Data System (C-RADS): Version 2023 UpdateJudy Yee et al. · Radiology · 2024 · PubMed · cited 26
- Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma CellsJames Brandon Reinecke et al. · Clinical Cancer Research · 2024 · PubMed · cited 24
- Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and TreatmentFauzia Ullah et al. · Cancers · 2024 · PubMed · cited 20
- Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura S. Samples et al. · Blood · 2025 · PubMed · cited 18
- American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adultsAdam S. DuVall et al. · Blood Advances · 2026 · PubMed · cited 14
- Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic NicheJames Brandon Reinecke et al. · Cancer Research · 2025 · PubMed · cited 14